Less than one in 10 individuals who could benefit from obesity jabs like Wegovy can access them, states the WHO as it issues its inaugural recommendations on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for increased and just availability to GLP-1 medication.
Based on forecasts, more than two billion will be obese by 2030 without intervention.
"Our latest guidelines recognises that obesity is a lifelong illness that can be addressed with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant hurdles to universal access to the jabs that can help people shift considerable body mass, says the body.
GLP-1 Therapy Scarcity
Even in the present best projected outlook, the production of these medications might only reach approximately 100 million people – less than 10% of eligible patients, per the health organization.
The guideline calls on nations and manufacturers to expand access, via strategies such as voluntary licensing.
A patent on semaglutide – the main component of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs replicate a biological compound to slow digestion, reduce hunger and increase feelings of fullness so individuals reduce food intake.
People commonly see weight reduction in the initial weeks of commencing the regular doses.
Evidence suggests users may put most of the weight back on after a year of stopping the treatment, when their normal appetite come back.
To be carrying excess weight elevates your chance for developing health problems, such as diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight impacts people in all nations and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
